|Articles|June 1, 2008
Bovell table 2
Table 2: Additional interventions required during follow-up.
Advertisement
SLT
ALT
2
0
5
10
17
7
14
15
10
1
1
0
49
33
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
2
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
3
FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD
4
FLORetina 2025: Weight and PMA drive foveal maturation in preterm infants
5









































